New drug combo tested for Tough-to-Treat leukemia

NCT ID NCT04657081

Ongoing Disease control Sponsor: Taiho Oncology, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing a combination of two oral drugs, ASTX727 and venetoclax, for adults newly diagnosed with acute myeloid leukemia (AML) who are age 75 or older, or who have other health problems that make them unable to receive standard intensive chemotherapy. The main goals are to see how the drugs interact in the body and to check if the combination is safe and effective at putting the leukemia into remission. The study is for adults who are not eligible for stronger initial treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Baptist MD Anderson Cancer Center

Jacksonville, Florida, 32207, United States
Baylor Scott & White Research Institute

Temple, Texas, 76508, United States
Boca Raton Clinical Research

Plantation, Florida, 33322, United States
Clinica Universidad de Navarra, Pamplona

Pamplona, Navarre, 31008, Spain
East Carolina University

Greenville, North Carolina, 27834, United States
Hackensack University of Medical Center

Hackensack, New Jersey, 07601, United States
Health Midwest Ventures Group, Inc.

Kansas City, Missouri, 64132, United States
Hospital Universitari i Politecnic La Fe

Valencia, 46026, Spain
Hospital Universitario Central de Asturias

Oviedo, Austrias, 33011, Spain
Hospital Universitario de Salamanca

Salamanca, 37007, Spain
Indiana University Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Institut Catala d'Oncologia-Hospital Duran i Reynals

L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Jewish General Hospital

Montreal, H3T 1E2, Canada
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, 17033, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
Stanford University

Palo Alto, California, 94306, United States
The Ohio State University

Columbus, Ohio, 43210, United States
The Ottawa Hospital, General Campus

Ottawa, Ontario, K1H 8L6, Canada
The Research Foundation of the State University of New York (SUNY)

Syracuse, New York, 13210, United States
The University of Chicago Medical Center

Chicago, Illinois, 60637, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
Universitario Gregorio Marañon

Madrid, 28007, Spain
University of Alberta

Edmonton, Alberta, T6G 2R3, Canada
University of Calgary - Health Sciences Centre

Calgary, Alberta, T2N 4N1, Canada
University of Massachusetts, Memorial Medical Center

Worcester, Massachusetts, 01655, United States
University of Rochester

Rochester, New York, 14627, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232-6307, United States
Weill Cornell Medical College

New York, New York, 10065, United States
Yale University

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA